Innodem Neurosciences signs strategic partnership agreement with Novartis

3 minute read
05 October 2021

On October 5, 2021, Innodem Neurosciences ("Innodem") announced that it had signed a multi-year partnership agreement with Novartis Pharmaceuticals Canada Inc. ("Novartis") to conduct a breakthrough clinical trial to help people living with multiple sclerosis (MS).

Innodem's AI-powered, patented, eye tracking software technology is embodied in a mobile application that turns a tablet into a device capable of capturing and analyzing Eye Movement Biomarkers (EMBs) and Gaze Mapping Biomarkers (GMBs) to assist a clinician's diagnosis and monitor MS disease progression.
Digital EMB and GMB tests are non-invasive and can be completed in minutes in the clinic's waiting room or by the patient at home. Remote self-testing is a major advantage during a pandemic and for people living with MS residing in rural areas who cannot easily access a neurologist.
Over the course of the trial, people living with MS will test twice a month and the data will be correlated with the current gold standard Expanded Disability Status Scale (EDSS), Brief International Cognitive Assessment for MS (BICAMS) and Multiple Sclerosis Functional Composite (MSFC) scores to assist clinicians in detecting subtle changes indicative of disease progression and that may not show up using magnetic resonance imaging (MRI).
Innodem management believes that the multi-year trial will demonstrate that novel digital EMBs and GMBs can measure these changes accurately, easily and cost-effectively. 
Founded in 2016, Innodem has developed patented mobile digital biomarking technology of neurodegenerative diseases such as MS, Alzheimer's disease, Parkinson's disease and related disorders, Frontotemporal Dementia and related disorders and Cancer-Related Cognitive Impairment. Innodem's mission is to provide easier ways to do remote testing for all stages of neurodegenerative diseases and cancer-related cognitive impairment.
Gowling WLG acted as legal counsel for Innodem in the negotiation of this complex commercial agreement with a team that included Olivier Therrien, Jean-François Vadeboncoeur and Georgi Paskalev. 

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.